Upsher-Smith Expands Portfolio with Sixth Product Launch in 2018
Maple Grove, MN – August 2, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added another product to its growing generic portfolio, supporting its commitment to expanding and diversifying its product offerings. The Company has launched four new products and two line extensions this year.
Upsher-Smith’s Bexarotene Capsules, 75 mg, an AB-rated generic version of the branded product, Targretin® (bexarotene) Capsules*, was approved by the U.S. Food and Drug Administration (FDA) on July 25, 2018.
“This is an exciting time for Upsher-Smith. Our portfolio is more diversified than ever before and we are optimistic that we will continue to grow given the record number of potential ANDA submissions planned over the next several years and key strategic partnerships we’ve formed,” said Rusty Field, President and CEO, Upsher-Smith.
Product Information
| Product | Strength | NDC # | Package Size |
| Bexarotene Capsules | 75 mg | 0832-0285-00 | Bottle of 100 |
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
| WARNING: BIRTH DEFECTS See full prescribing information for complete boxed warning. Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. Bexarotene must not be administered to a pregnant woman. |
Contact: Elizabeth Likly
Kovak-Likly Communications
203-762-8833, elikly@klcpr.com